secwatch.observer — SEC 8-K summary
======================================

Issuer:     Attovia Therapeutics, Inc. (ATTO)
CIK:        0002058707
Form:       8-K
Filed at:   2026-09-02T20:17:18+00:00
Accession:  0001193125-26-380215
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Attovia Q2 2026 net loss $20.7M; ATTO-1310 proof-of-concept; IPO funds runway to 2030
--------------------------------------------------------------------------------

- Q2 2026 net loss $20.7M vs $14.4M year ago; R&D $18.9M vs $13.6M; collaboration revenue $0.5M.
- Cash $115.1M at 6/30/26; plus $305.4M net IPO proceeds (Aug '26) extends runway into 2030.
- ATTO-1310 Phase 1b shows rapid itch relief in chronic pruritus and high-itch AD; full data Q4 2026.
- Phase 2 studies in CPUO and high-itch AD planned 1H 2027; Phase 1 for ATTO-2306/1091 also 1H 2027.
- IPO gross proceeds $332.4M; board strengthened with John W. Smither appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2058707/000119312526380215/0001193125-26-380215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2058707/000119312526380215/atto-20260902.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-380215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer